{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:38:14Z","timestamp":1790091494039,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.4158\/ep-2019-0607","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T15:32:33Z","timestamp":1588001553000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S3","title":["Concentrated Insulins: Clinical Update of Therapeutic Options"],"prefix":"10.1016","volume":"26","author":[{"given":"Guillermo E.","family":"Umpierrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Einhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet B.","family":"McGill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP-2019-0607_bb0005","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract."},{"key":"10.4158\/EP-2019-0607_bb0010","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.tem.2017.05.001","article-title":"Gut microbiota, endocrine-disrupting chemicals, and the diabetes epidemic","volume":"28","author":"Velmurugan","year":"2017","journal-title":"Trends Endocrinol Metab."},{"key":"10.4158\/EP-2019-0607_bb0015","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/dci18-0007","article-title":"Economic costs of diabetes in the U.S. in 2017","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care."},{"key":"10.4158\/EP-2019-0607_bb0020","unstructured":"Centers for Disease Control and Prevention. Estimates of diabetes burden in the United States. National Diabetes Statistics Report."},{"key":"10.4158\/EP-2019-0607_bb0025","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care."},{"key":"10.4158\/EP-2019-0607_bb0035","doi-asserted-by":"crossref","first-page":"15019","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus","volume":"1","author":"DeFronzo","year":"2015","journal-title":"Nat Rev Dis Primers."},{"key":"10.4158\/EP-2019-0607_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2010.09.010","article-title":"Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes","volume":"60","author":"Nyenwe","year":"2011","journal-title":"Metabolism."},{"key":"10.4158\/EP-2019-0607_bb0045","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrendo.2014.17","article-title":"Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment","volume":"10","author":"Fonseca","year":"2014","journal-title":"Nat Rev Endocrinol."},{"key":"10.4158\/EP-2019-0607_bb0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1399-5448.2009.00519.x","article-title":"Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study","volume":"11","author":"Liu","year":"2010","journal-title":"Pediatr Diabetes."},{"key":"10.4158\/EP-2019-0607_bb0055","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2016.6361","article-title":"Trends in obesity prevalence among children and adolescents in the United States, 1988-1994 through 2013-2014","volume":"315","author":"Ogden","year":"2016","journal-title":"JAMA."},{"key":"10.4158\/EP-2019-0607_bb0060","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1210\/er.2017-00191","article-title":"Obesity in type 1 diabetes: pathophysiology, clinical impact, and mechanisms","volume":"39","author":"Corbin","year":"2018","journal-title":"Endocr Rev."},{"issue":"1 Pt 2","key":"10.4158\/EP-2019-0607_bb0065","doi-asserted-by":"crossref","first-page":"136","DOI":"10.7326\/0003-4819-124-1_Part_2-199601011-00011","article-title":"United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus","volume":"124","author":"Turner","year":"1996","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP-2019-0607_bb0070","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA."},{"key":"10.4158\/EP-2019-0607_bb0075","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care."},{"key":"10.4158\/EP-2019-0607_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2010.08.006","article-title":"Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review","volume":"92","author":"Giugliano","year":"2011","journal-title":"Diabetes Res Clin Pract."},{"key":"10.4158\/EP-2019-0607_bb0085","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/MED.0b013e3283514e13","article-title":"What causes the insulin resistance underlying obesity?","volume":"19","author":"Hardy","year":"2012","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"key":"10.4158\/EP-2019-0607_bb0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.mam.2015.09.003","article-title":"Molecular pathophysiology of hepatic glucose production","volume":"46","author":"Sharabi","year":"2015","journal-title":"Mol Aspects Med."},{"key":"10.4158\/EP-2019-0607_bb0095","first-page":"183","article-title":"Insulin management of type 2 diabetes mellitus","volume":"84","author":"Petznick","year":"2011","journal-title":"Am Fam Physician."},{"key":"10.4158\/EP-2019-0607_bb0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2337\/diaclin.34.2.97","article-title":"Treatment approach to patients with severe insulin resistance","volume":"34","author":"Church","year":"2016","journal-title":"Clin Diabetes."},{"key":"10.4158\/EP-2019-0607_bb0105","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.diabres.2010.06.025","article-title":"Clinical approach to the patient with diabetes mellitus and very high insulin requirements","volume":"90","author":"Ovalle","year":"2010","journal-title":"Diabetes Res Clin Pract."},{"key":"10.4158\/EP-2019-0607_bb0110","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2146\/ajhp090554","article-title":"Use of concentrated insulin human regular (U-500) for patients with diabetes","volume":"67","author":"Segal","year":"2010","journal-title":"Am J Health Syst Pharm."},{"key":"10.4158\/EP-2019-0607_bb0115","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2337\/diaspect.29.3.136","article-title":"An overview of concentrated insulin products","volume":"29","author":"Painter","year":"2016","journal-title":"Diabetes Spectr."},{"key":"10.4158\/EP-2019-0607_bb0120","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-like peptide 1 receptor agonists for type 2 diabetes","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diabetes Spectr."},{"key":"10.4158\/EP-2019-0607_bb0125","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/pgmj.2008.073379","article-title":"Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus","volume":"85","author":"Crasto","year":"2009","journal-title":"Postgrad Med J."},{"issue":"suppl 8","key":"10.4158\/EP-2019-0607_bb0130","first-page":"S38","article-title":"Concentrated insulins: a review and recommendations","volume":"34","author":"Gonzalvo","year":"2017","journal-title":"Fed Pract."},{"key":"10.4158\/EP-2019-0607_bb0135","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/1753-0407.12861","article-title":"Concentrated insulins: history and critical reappraisal","volume":"11","author":"Heinemann","year":"2019","journal-title":"J Diabetes."},{"key":"10.4158\/EP-2019-0607_bb0145","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/cpdd.221","article-title":"Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U\/mL relative to insulin lispro (Humalog\u00ae) 100 U\/mL","volume":"5","author":"de la Pe\u00f1a","year":"2016","journal-title":"Clin Pharmacol Drug Dev."},{"key":"10.4158\/EP-2019-0607_bb0150","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40261-013-0096-7","article-title":"A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U\/mL formulations of ultra-long-acting insulin degludec","volume":"33","author":"Korsatko","year":"2013","journal-title":"Clin Drug Investig."},{"key":"10.4158\/EP-2019-0607_bb0155","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2337\/dc12-1668","volume":"36","author":"Meneghini","year":"2013","journal-title":"Diabetes Care."},{"key":"10.4158\/EP-2019-0607_bb0160","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1463-1326.2012.01627.x","article-title":"Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes","volume":"14","author":"Heise","year":"2012","journal-title":"Diabetes Obes Metab."},{"key":"10.4158\/EP-2019-0607_bb0165","doi-asserted-by":"crossref","first-page":"8726046","DOI":"10.1155\/2018\/8726046","article-title":"Efficacy and safety of insulin degludec versus insulin glargine: a systematic review and meta-analysis of fifteen clinical trials","volume":"2018","author":"Liu","year":"2018","journal-title":"Int J Endocrinol."},{"key":"10.4158\/EP-2019-0607_bb0170","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2147\/DDDT.S132581","article-title":"United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes","volume":"11","author":"Rendell","year":"2017","journal-title":"Drug Des Devel Ther."},{"key":"10.4158\/EP-2019-0607_bb0175","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2337\/dc12-1205","article-title":"Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)","volume":"35","author":"Zinman","year":"2012","journal-title":"Diabetes Care."},{"key":"10.4158\/EP-2019-0607_bb0180","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(12)60205-0","article-title":"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basalbolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial","volume":"379","author":"Garber","year":"2012","journal-title":"Lancet."},{"key":"10.4158\/EP-2019-0607_bb0185","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(12)60204-9","article-title":"Insulin degludec, an ultralongacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-totarget non-inferiority trial","volume":"379","author":"Heller","year":"2012","journal-title":"Lancet."},{"key":"10.4158\/EP-2019-0607_bb0190","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.2337\/dc12-2329","volume":"36","author":"Gough","year":"2013","journal-title":"Diabetes Care."},{"key":"10.4158\/EP-2019-0607_bb0195","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s13300-018-0511-4","article-title":"Impact of insulin degludec in type 2 diabetes: real-world data on effectiveness and safety","volume":"9","author":"Ponzani","year":"2018","journal-title":"Diabetes Ther."},{"key":"10.4158\/EP-2019-0607_bb0200","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s13300-019-00722-y","article-title":"Switching patients with type 1 diabetes to insulin degludec from other basal insulins: realworld data of effectiveness and safety","volume":"11","author":"Ponzani","year":"2020","journal-title":"Diabetes Ther."},{"key":"10.4158\/EP-2019-0607_bb0205","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1080\/17425255.2016.1245722","article-title":"Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes","volume":"12","author":"Hurren","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"10.4158\/EP-2019-0607_bb0210","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00125-019-05080-9","article-title":"Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, headto-head CONCLUDE trial","volume":"63","author":"Philis-Tsimikas","year":"2020","journal-title":"Diabetologia."},{"key":"10.4158\/EP-2019-0607_bb0215","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1517\/14712598.2014.970633","article-title":"U300, a novel long-acting insulin formulation","volume":"14","author":"Sutton","year":"2014","journal-title":"Expert Opin Biol Ther."},{"key":"10.4158\/EP-2019-0607_bb0220","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1177\/1060028015597915","article-title":"New insulin glargine 300 U\/mL for the treatment of type 1 and type 2 diabetes mellitus","volume":"49","author":"Goldman","year":"2015","journal-title":"Ann Pharmacother."},{"key":"10.4158\/EP-2019-0607_bb0225","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.2337\/dc14-0991","article-title":"New insulin glargine 300 units\/mL versus glargine 100 units\/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)","volume":"37","author":"Riddle","year":"2014","journal-title":"Diabetes Care."},{"key":"10.4158\/EP-2019-0607_bb0230","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2337\/dc14-0990","article-title":"New insulin glargine 300 units\/mL versus glargine 100 units\/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)","volume":"37","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Diabetes Care."},{"key":"10.4158\/EP-2019-0607_bb0235","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/dom.12438","article-title":"New insulin glargine 300 U\/ml compared with glargine 100 U\/ml in insulinnaive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)","volume":"17","author":"Bolli","year":"2015","journal-title":"Diabetes Obes Metab."},{"key":"10.4158\/EP-2019-0607_bb0240","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc15-0249","article-title":"New insulin glargine 300 Units\/mL versus glargine 100 Units\/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4)","volume":"38","author":"Home","year":"2015","journal-title":"Diabetes Care."},{"key":"10.4158\/EP-2019-0607_bb0245","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/dme.13847","article-title":"A multicentre, UK, retrospective, observational study to assess the effectiveness of insulin glargine 300 units\/ml in treating people with type 1 diabetes mellitus in routine clinical practice (SPARTA)","volume":"36","author":"Pang","year":"2019","journal-title":"Diabet Med."},{"key":"10.4158\/EP-2019-0607_bb0250","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1007\/s12325-019-00983-w","article-title":"Characteristics of patients with type-1 or type-2 diabetes receiving insulin glargine U300: an analysis of 7268 patients based on the DPV and DIVE registries","volume":"36","author":"van Mark","year":"2019","journal-title":"Adv Ther."},{"key":"10.4158\/EP-2019-0607_bb0255","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s13300-019-0568-8","article-title":"Rates of hypoglycemia predicted in patients with type 2 diabetes on insulin glargine 300 U\/ml versus first- and second-generation basal insulin analogs: the Real-World LIGHTNING Study","volume":"10","author":"Pettus","year":"2019","journal-title":"Diabetes Ther."},{"key":"10.4158\/EP-2019-0607_bb0260","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.73","article-title":"Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units\/mL versus other basal insulin in a real-world setting","volume":"2","author":"Zhou","year":"2019","journal-title":"Endocrinol Diabetes Metab."},{"key":"10.4158\/EP-2019-0607_bb0265","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4158\/EP15959.OR","article-title":"Effect of total daily dose on efficacy, dosing, and safety of 2 dose titration regimens of human regular U500 insulin in severely insulin-resistant patients with type 2 diabetes","volume":"22","author":"Wysham","year":"2016","journal-title":"Endocr Pract."},{"key":"10.4158\/EP-2019-0607_bb0270","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.2337\/dc11-0721","article-title":"Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects","volume":"34","author":"de la Pe\u00f1a","year":"2011","journal-title":"Diabetes Care."},{"key":"10.4158\/EP-2019-0607_bb0275","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2014-000074","article-title":"Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study","volume":"3","author":"Eby","year":"2015","journal-title":"BMJ Open Diabetes Res Care."},{"key":"10.4158\/EP-2019-0607_bb0280","doi-asserted-by":"crossref","first-page":"721","DOI":"10.4158\/EP.13.7.721","article-title":"Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes","volume":"13","author":"Bulchandani","year":"2007","journal-title":"Endocr Pract."},{"key":"10.4158\/EP-2019-0607_bb0285","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4158\/ep.9.3.181","article-title":"A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series","volume":"9","author":"Knee","year":"2003","journal-title":"Endocr Pract."},{"key":"10.4158\/EP-2019-0607_bb0290","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/dom.13947","article-title":"Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: the VIVID study","volume":"22","author":"Grunberger","year":"2020","journal-title":"Diabetes Obes Metab."},{"key":"10.4158\/EP-2019-0607_bb0295","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/193229681200600229","article-title":"Clinical use of U-500 regular insulin: review and meta-analysis","volume":"6","author":"Reutrakul","year":"2012","journal-title":"J Diabetes Sci Technol."},{"key":"10.4158\/EP-2019-0607_bb0300","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.diabres.2018.12.007","article-title":"Concentrated insulins in current clinical practice","volume":"148","author":"Schloot","year":"2019","journal-title":"Diabetes Res Clin Pract."},{"key":"10.4158\/EP-2019-0607_bb0305","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1210\/jcem.87.3.8341","article-title":"Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes","volume":"87","author":"Umpierrez","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP-2019-0607_bb0310","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2337\/dc09-9029","article-title":"American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control","volume":"32","author":"Moghissi","year":"2009","journal-title":"Diabetes Care."},{"key":"10.4158\/EP-2019-0607_bb0315","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/jc.2011-2098","article-title":"Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society clinical practice guideline","volume":"97","author":"Umpierrez","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP-2019-0607_bb0320","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jdiacomp.2017.02.008","article-title":"A retrospective review of insulin requirements in patients using U-500 insulin hospitalized to a Veterans Affairs Hospital","volume":"31","author":"Kedia","year":"2017","journal-title":"J Diabetes Complications."},{"key":"10.4158\/EP-2019-0607_bb0325","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.4158\/EP161355.OR","article-title":"Evaluation of total daily dose and glycemic control for patients taking U-500 regular insulin admitted to the hospital","volume":"22","author":"Paulus","year":"2016","journal-title":"Endocr Pract."},{"key":"10.4158\/EP-2019-0607_bb0330","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4158\/EP14151.OR","article-title":"U-500 regular insulin use in hospitalized patients","volume":"21","author":"Tripathy","year":"2015","journal-title":"Endocr Pract."},{"key":"10.4158\/EP-2019-0607_bb0335","article-title":"A randomized controlled trial comparing glargine U300 and glargine U100 for the inpatient management of medicine and surgery patients with type 2 diabetes: Glargine U300 Hospital Trial","volume":"9","author":"Pasquel","year":"2020","journal-title":"Diabetes Care."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20428307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20428307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:07:35Z","timestamp":1761516455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20428307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":65,"alternative-id":["S1530891X20428307"],"URL":"https:\/\/doi.org\/10.4158\/ep-2019-0607","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concentrated Insulins: Clinical Update of Therapeutic Options","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP-2019-0607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}